vida: extract claims from 2026-05-07-all-of-us-glp1-sud-75pct-lower-odds

- Source: inbox/queue/2026-05-07-all-of-us-glp1-sud-75pct-lower-odds.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -189,3 +189,10 @@ Semaglutide + CBT for AUD achieved 41.1% reduction in heavy drinking days with N
 **Source:** NBC News/Pharmacy Times synthesis April 2026, Session 22 Science 2025 VTA dopamine circuit paper
 
 GLP-1 receptor agonists show evidence across multiple substance use disorders beyond AUD: (1) Opioid Use Disorder: liraglutide produced ~40% reduction in opioid craving in small RCT; semaglutide significantly reduced opioid overdose risk in 1-year follow-up for T2D+OUD patients (real-world data). (2) Nicotine: exenatide + NRT increased 7-day abstinence vs placebo at week 6, though long-term findings mixed; SEMALCO trial showed reduced cigarettes/day as secondary endpoint in AUD+smoking subgroup. (3) Cocaine/stimulants: liraglutide reduces operant methamphetamine intake in rats (preclinical only). Population-level evidence: among people with pre-existing SUD on GLP-1s, fewer ER visits, hospitalizations, and deaths across substance categories (observational data). As of April 2026: 33 clinical trials for SUD (15 AUD, 9 nicotine, 4 OUD, 4 cocaine). Evidence strength hierarchy: AUD > OUD > nicotine > cocaine.
+
+
+## Extending Evidence
+
+**Source:** Abegaz et al., Frontiers in Psychiatry 2026
+
+The All of Us study demonstrates GLP-1 effects extend across four distinct substance categories (alcohol, opioids, nicotine, cocaine) with similar effect sizes (OR 0.25-0.32), suggesting a shared reward circuit mechanism rather than substance-specific pharmacology. The cocaine use disorder effect size (OR=0.25, 75% reduction) is particularly notable as no behavioral intervention produces comparable CUD reduction, supporting a dopaminergic reward pathway as the common mechanism across all substance types.

domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md

@@ -46,3 +46,10 @@ VigiBase pharmacovigilance analysis shows eating disorder signals with aROR 4.17
 **Source:** NBC News/Pharmacy Times April 2026
 
 Critical limitation applies across all SUD evidence: all human data comes from patients with comorbid metabolic disease (T2D or obesity). Whether GLP-1s work for SUD without metabolic comorbidity is unknown and largely unstudied. This constraint affects not just AUD but the entire SUD evidence base — OUD, nicotine, and cocaine trials all recruit from metabolically compromised populations.
+
+
+## Supporting Evidence
+
+**Source:** Abegaz et al., Frontiers in Psychiatry 2026
+
+All of Us AUD cohort (n=22,652) showed OR=0.26 for GLP-1 exposure after propensity score matching for diabetes/obesity status, confirming the AUD effect persists in metabolically diverse populations. This adds to the JAMA Psychiatry RCT evidence (41% heavy drinking reduction in obesity+AUD) and Swedish cohort data, forming a three-study convergence across observational, within-individual, and RCT designs.

domains/health/glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients.md

@@ -24,3 +24,10 @@ A systematic review and meta-analysis published in eClinicalMedicine synthesized
 **Source:** Osmind clinical article Q1 2026, citing 142K participant observational study
 
 Observational data from 142,000 participants showed 75% lower odds of developing ANY substance use disorder with GLP-1 exposure (not just AUD). Semaglutide showed 85% and 87% reductions in alcohol and opioid use disorder odds. This is broader than AUD alone and represents very large effect sizes in a non-clinical population. Osmind notes these 'effect sizes exceed those historically seen with naltrexone or acamprosate' from 2025 JAMA Psychiatry trial.
+
+
+## Extending Evidence
+
+**Source:** Abegaz et al., Frontiers in Psychiatry 2026
+
+All of Us nested case-control study (n=87,494 across four SUD subtypes) found GLP-1 exposure associated with OR=0.25 (95% CI 0.22-0.30) for any substance use disorder — 75% lower odds. This represents the largest observational effect size in the GLP-1 SUD literature. Specific subtypes: AUD OR=0.26 (74% reduction, n=22,652), OUD OR=0.31 (69% reduction, n=13,226), NUD OR=0.32 (68% reduction, n=42,320), CUD OR=0.25 (75% reduction, n=9,296). The convergence of three independent designs — this observational study (OR=0.25), Swedish within-individual cohort (47% SUD worsening reduction), and JAMA Psychiatry RCT (41% heavy drinking reduction, NNT 4.3) — with consistent direction despite different populations and methods strengthens causal inference beyond any single study.

inbox/archive/health/2026-05-07-all-of-us-glp1-sud-75pct-lower-odds.md

@@ -7,10 +7,13 @@ date: 2026-03-10
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: high
 tags: [glp-1, substance-use-disorder, addiction, observational-study, all-of-us]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content